What You Will Learn

Please join Carterra at our upcoming symposium in Boston, MA. You will spend the day learning about high-throughput drug discovery and antibody therapeutics with some of the industry’s leading scientists. Our speakers will present new ways of looking at discovery, applications, and workflows, including HT-SPR. The topics you'll hear about include:

Antibody discovery in 90 days! Screening, identification & characterization
New methods in DELs, PROTACs and other formats
New technology and innovations during the pandemic
Data analysis routines & automation
Best practices in analyzing SPR data

Network with your peers. Lunch will be provided. Registration is required as seating is limited.

Please download the Symposium Survey if you plan to attend.

Agenda

8:45am – 9:00am	Arrive and Check-in
9:00am – 9:30am	Networking and Coffee/Tea
9:30am – 9:45am	Symposium Begins—Welcome
9:45am – 10:30am	Sharon L. Schendel, PhD, Program Manager, La Jolla Institute for Immunology Keynote Address—From Alpha to Omicron: A global consortium study to identify broadly reactive SARS-CoV2 therapeutic antibodies
	Abstract: The Coronavirus Immunotherapeutic Consortium (CoVIC) was formed to develop prevention and therapeutic strategies against SARS-CoV-2 that could be mobilized in low- and middle-income countries. With now almost 400 unique antibodies, CoVIC has mapped the epitope landscape on the SARS-CoV-2 Spike protein using the Carterra LSA platform. This information, coupled with high throughput viral neutralization screens and in vivo protection studies, has revealed key communities of receptor-binding domain (RBD)-targeted antibodies that are resistant to major emerging variants. These results provide a framework for selecting antibody treatment cocktails and understanding how viral variants might affect antibody therapeutic efficacy.
10:30am – 11:00pm	Noah T. Ditto, Technical Product Manager, Carterra New Applications Using HT-SPR Technology
	Abstract: From kinetics to epitope characterization, HT-SPR has become an indispensable technology for the characterization of biotherapeutics. This presentation will focus on recently developed assays that expand the versatility of HT-SPR in the biotherapeutic space as well as move into new areas drug discovery. Topics include potency-based assays in addition to approaches focused on characterization of small molecule formats including targeted protein degraders (TPDs) and DNA encoded libraries (DELs).
11:00am – 11:30am	Break and Networking
11:30pm – 12:00pm	M. Frank Erasmus, PhD, Head, Bioinformatics, Specifica, Inc. Linking NGS to Biophysical Measurements - Important Insights into NGS-Guided Selection Strategies from a SARS-CoV-2 Discovery Campaign
	Abstract: Specifica has recently built AbXtract™, a cloud-based bioinformatics platform, in collaboration with OpenEye Scientific to efficiently explore the NGS/Sanger sequence space to select leads with broad paratope coverage. In this webinar, we will showcase how we used our Generation 3 Antibody Library Platform and AbXtract to select antibodies against the SARS-CoV-2 Spike protein and its subunits. Using Carterra’s LSA, we were able to screen >200 antibodies to gather high-quality kinetics and binning data, the majority of which exhibited sub-nanomolar affinities (down to ~13pM), many with distinct binding profiles. Further, we will show how routine biophysical measurements collected from the LSA are incorporated into our informatics platform, providing a robust feedback loop, allowing for marginal improvements of our machine learning models and heuristics that serve to enhance our lead discovery pipeline.
12:00pm – 1:00pm	Lunch and Networking
1:00pm – 1:30pm	Maria McGresham, PhD, Field Applications Scientist, Carterra Best Practices for Designing and Analyzing Epitope Binning Experiments Using the Carterra LSA and Epitope Software
	Abstract: We will describe practical guidelines for designing, executing and analyzing epitope binning assays using Carterra’s LSA and industry-leading Epitope™ software. We will provide tips and tricks for leveraging the power of our software to groom a data set, remove unnecessary complexity, and apply community analysis while retaining sufficient nuance to most accurately describe the epitope landscape.
1:30pm – 2:00pm	Mike Brown, Senior Scientist, Adimab LLC More is Better – High-Throughput and High-Capacity Binding Characterization Assays for Antibody Discovery
	Abstract: Binding characterization assays are a critical component of the early discovery process. These assays validate and rank order candidate molecules and can help weed out samples with undesirable properties. When it comes to performing these experiments, more is better - more samples, more reagents, more assays, more throughput, more data. Here we will show how incorporating the Carterra LSA into our discovery platform has allowed us to do more.
2:00pm – 2:30pm	Break and Networking
2:30pm – 3:00pm	Heather Schwoebel, Chief Business Officer, Alloy Therapeutics Lucy Liu, PhD, Senior Director and Head of Protein Analytics, Alloy Therapeutics Fully Integrated Antibody Discovery for the Biotechnology Ecosystem
	Abstract: Alloy Therapeutics is a biotechnology ecosystem company that democratizes access to tools, technologies, services, and capabilities that are foundational for discovering and developing therapeutic biologics. Its fully integrated discovery service offering, DeepImmune™, deploys in vivo, in vitro, and in silico discovery and optimization technologies to find partners the best therapeutic antibody candidates. Alloy Chief Business Officer Heather Schwoebel and Head of Protein Analytics Lucy Liu will discuss how the Carterra LSA fits into this workflow and supports its efforts to enable the global scientific community to make better medicine together.
3:00pm – 4:00pm	Networking and 100th LSA Celebration – Sponsored by Alloy Therapeutics
4:00pm	Symposium Ends

What You Will Learn

Register Here

Agenda